Dopamine: an old target in a new therapy

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Dopamine is a neurotransmitter involved in emotions and has roles in cancer growth and tumor angiogenesis.
• Peripheral dopamine is linked to tumorigenic events.
• Current anti-angiogenesis drugs have limitations.

Purpose of the Study:

• To evaluate dopamine as a potential anti-vascular endothelial growth factor A (VEGF-A) agent for treating tumor angiogenesis.
• To investigate dopamine's efficacy in preventing chemotherapy-induced side effects.

Main Methods:

• Pre-clinical studies were conducted.
• The study assessed dopamine's effects on tumor angiogenesis.
• Dopamine's impact on 5-fluorouracil (5FU)-induced neutropenia in tumor-bearing mice was examined.

Main Results:

• Dopamine demonstrated potential as an anti-VEGF-A agent.
• Dopamine was found to be less expensive, have fewer side effects, and be more sensitive than existing drugs for treating tumor angiogenesis.
• Dopamine successfully prevented 5FU-induced neutropenia in tumor-bearing mice.

Conclusions:

• Dopamine presents a novel therapeutic strategy for managing cancer growth.
• Dopamine may be a valuable agent for managing chemotherapy-related disorders.
• These findings suggest dopamine as a promising, cost-effective, and safe alternative in cancer treatment.